TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
19.02
+0.03 (+0.16%)
At close: 4:01PM EST

19.050 +0.03 (0.16%)
After hours: 5:53PM EST

Stock chart is not supported by your current browser
Previous Close18.99
Open19.05
Bid18.900 x 1800
Ask19.100 x 21500
Day's Range18.94 - 19.29
52 Week Range15.70 - 25.96
Volume8,942,906
Avg. Volume11,564,075
Market Cap19.376B
Beta (3Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-10.869
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est23.19
Trade prices are not sourced from all markets
  • InvestorPlace9 hours ago

    Should Warren Buffett — And You — Buy More TEVA Stock Right Now?

    The last few years for drug-maker Teva Pharmaceuticals (NASDAQ:TEVA) haven’t exactly been that wonderful. TEVA stock has plunged on a series of mishaps and issues. In fact, TEVA has fallen enough that America’s favorite value investor, Warren Buffett, has taken a huge interest in the stock over the last few quarters.

  • Reuters9 hours ago

    Teva Pharm to move headquarters to Tel Aviv

    Israel-based Teva Pharmaceutical Industries said on Thursday it was moving its headquarters to Tel Aviv as part of a global restructuring. Teva, the world's largest generic drugmaker, said its new base will replace a number of sites located in the area of Petah Tikva, a city just outside of Tel Aviv -- Israel's commercial capital. Teva has been restructuring itself over the past year to deal with its massive debt, including lay-offs, site closings and the combining of divisions.

  • Zacks2 days ago

    Teva (TEVA) Stock Poised to Record Big Gains in 2019?

    Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.

  • Warren Buffett's 10 Big Stock Losers
    Investopedia2 days ago

    Warren Buffett's 10 Big Stock Losers

  • InvestorPlace3 days ago

    3 Big Stock Charts for Tuesday: Micron Technology, Fortive and Morgan Stanley

    Headed into Tuesday’s session, stock charts of Micron Technology (NASDAQ:MU), Fortive (NYSE:FTV) and Morgan Stanley (NYSE:MS) are worth a closer look. Three weeks ago we pointed out how Micron Technology shares were trending lower, framed by a well-defined falling trading range. It may well be en route to the lower edge of that trading range again, but if it is, there’s a much bigger technical support line that will have to snap first.

  • Zacks2 days ago

    Generic Drugmakers Down on Allegations of Price Fixing

    An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.

  • Generic-drug stocks slammed by report of expanded price-fixing probe
    MarketWatch3 days ago

    Generic-drug stocks slammed by report of expanded price-fixing probe

    Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.

  • ACCESSWIRE3 days ago

    Today's Research Reports on Trending Tickers: Teva Pharmaceutical and Innovate Biopharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Several generic drug stocks were falling into the red on Monday, including Teva Pharmaceuticals, after Wall Street learned that a Washington Post report said an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry. Shares of Innovate Biopharmaceuticals were soaring despite any news from the company. Innovate Biopharmaceuticals, Inc.

  • Why Teva Pharmaceutical Industries, Tivity Health, and Marine Products Slumped Today
    Motley Fool3 days ago

    Why Teva Pharmaceutical Industries, Tivity Health, and Marine Products Slumped Today

    Learn what held these companies' stocks back on a choppy day for the market.

  • MarketWatch3 days ago

    Generic drug makers stocks fall sharply after report of expanded price-fixing probe

    Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.

  • Zacks Small Cap Research3 days ago

    ATRS: Xyosted & Epi Pen Available for Sale

    The last week of November was a good one for Antares Pharma, Inc. (ATRS) with both Epi Pen and Xyosted now commercially available. Teva Pharmaceuticals (TEVA) announced on November 27th that the recently approved AB-rated generic Epinephrine Pen is now available in the United States. For the remainder of 2018, only the Epi Pen 0.3 mg version will be available in limited quantities with additional supply of the 0.3 mg version and Epi Pen Jr (0.15 mg) to be available in 2019.

  • Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy?
    Insider Monkey4 days ago

    Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • Roche's Kadcyla Halves Death Risk in Breast Cancer Study
    Zacks7 days ago

    Roche's Kadcyla Halves Death Risk in Breast Cancer Study

    Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

  • Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval
    Market Realist7 days ago

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, announced that the US FDA provided 510(K) clearance for its Ultra multifocal contact lenses for use in patients with astigmatism. The Ultra multifocal toric lens will be the first of its kind available for standard use.

  • Mylan Expands Recall of Valsartan to All Unexpired Lots
    Zacks8 days ago

    Mylan Expands Recall of Valsartan to All Unexpired Lots

    Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.

  • Generics and Biosimilar Business Is Major Growth Driver for Teva
    Market Realist9 days ago

    Generics and Biosimilar Business Is Major Growth Driver for Teva

    How Is Teva Pharmaceutical Positioned in 2018? On November 29, Celltrion issued a press release announcing FDA approval of Truxima, a biosimilar version of Roche Holdings’ (RHHBY) Rituxan in three indications. On October 6, 2016, Teva Pharmaceutical (TEVA) issued a press release announcing a partnership with Celltrion for the commercialization of biosimilar versions of Rituxan and Herceptin in the US and Canada.

  • Roche Announces Positive Data on Venclexta/Venclyxto at ASH
    Zacks9 days ago

    Roche Announces Positive Data on Venclexta/Venclyxto at ASH

    Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.

  • Reuters9 days ago

    U.S. justices wrestle with patent arguments for anti-nausea drug

    U.S. Supreme Court justices on Tuesday grappled with a Swiss pharmaceutical company's effort to salvage a patent behind its lucrative anti-nausea drug in a case that could make it easier to cancel key patents, especially among smaller drugmakers. The justices asked tough questions of both sides during an hour of oral arguments in an appeal by Helsinn Healthcare S.A. of a lower court's decision to invalidate its patent on Aloxi, which paved the way for Israel-based Teva Pharmaceutical Industries to launch a generic version of the drug in March. Aloxi is used to prevent nausea and vomiting in patients receiving chemotherapy.

  • Austedo Is on Solid Growth Trajectory in 2018
    Market Realist9 days ago

    Austedo Is on Solid Growth Trajectory in 2018

    How Is Teva Pharmaceutical Positioned in 2018? On April 3, 2017, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Austedo for chorea associated with Huntington’s disease. According to Teva Pharmaceutical’s third-quarter earnings conference call, almost 40,000 people in the US suffer from Huntington’s disease.

  • Ajovy Is a New Growth Driver for Teva Pharmaceutical
    Market Realist9 days ago

    Ajovy Is a New Growth Driver for Teva Pharmaceutical

    How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.

  • What Teva Pharmaceutical Predicts for Expenses in 2018
    Market Realist10 days ago

    What Teva Pharmaceutical Predicts for Expenses in 2018

    How Is Teva Pharmaceutical Positioned in 2018? On December 14, 2017, Teva Pharmaceutical (TEVA) issued a press release announcing a restructuring plan to reduce its cost base by $3.0 billion from $16.3 billion in fiscal 2017 to $13.3 billion in fiscal 2019. According to Teva Pharmaceutical’s third-quarter earnings conference call, since the beginning of the restructuring program, the company has already reduced its manpower by 9,100.

  • Famous Stocks Warren Buffett Bought and Sold
    GOBankingRates10 days ago

    Famous Stocks Warren Buffett Bought and Sold

    These are the moves Berkshire Hathaway made this year.

  • A Look at Teva Pharmaceutical’s Earnings Projections for 2018
    Market Realist10 days ago

    A Look at Teva Pharmaceutical’s Earnings Projections for 2018

    In its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) raised non-GAAP operating income guidance for fiscal 2018 from its projection in August 2018 of $4.3 billion–$4.6 billion to $4.6 billion–$4.8 billion. In February 2018, the company had projected its non-GAAP operating income for fiscal 2018 to fall in the range of $4.0 billion–$4.3 billion.

  • What Are Teva Pharmaceutical’s Revenue Projections for 2018?
    Market Realist10 days ago

    What Are Teva Pharmaceutical’s Revenue Projections for 2018?

    How Is Teva Pharmaceutical Positioned in 2018? During its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) raised the lower end of its revenue guidance for fiscal 2018 from its projection in August 2018 of $18.5 billion to $19.0 billion to $18.6 billion to $19.0 billion. In the third quarter, Teva Pharmaceutical reported total revenues of $4.53 billion, which is a YoY decline of 19.4%.

  • AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
    Zacks10 days ago

    AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018

    AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.